Mark Trusheim is founder of Co-Bio Consulting, LLC as well as Executive in Residence and Visiting Scholar at the MIT Sloan School of Management and a Special Government Employee for the FDA’s Office of the Commissioner.
He is a former member of the Massachusetts Biotechnology Council’s Board of Directors, which helps its over 500 members succeed in the state. In 2004 he further served as the Interim President of the MBC, leading its successful legislative agenda, its expansion of MassBioEd education programs and its continued membership growth.
As an entrepreneur, Mark founded and was the first President and CEO of Cantata Laboratories. Cantata marketed clinical diagnostics and pharmaceutical biomarker services based on its biochemical profiling platform.
Prior to Cantata, Mark spent over 10 years at Monsanto/Pharmacia, culminating his career there as Co-President and Chief Operating Officer of Cereon Genomics, LLC. Located in Cambridge, Massachusetts, Cereon was created in 1997 by Monsanto as part of a $500M collaboration with Millennium Pharmaceuticals. Prior to his position at Cereon, Mark was responsible for Monsanto's external genomics relationships and held roles of Vice President in the Health & Wellness Sector, Marketing Director in Searle Pharmaceutical and Director in Agriculture Division Strategy.
Mark spent the first half of his career in the high tech industry working at both Wang Laboratories in computer hardware and the start-up Kenan Systems Corporation in software services which exited to Lucent for >$1 billion.
He holds degrees in Chemistry from Stanford University and Management from MIT.